GENERICS

October 13, 2017

Biosimilar Milestone

Does the first generic biologic cancer medication portend things to come?

June 16, 2017

Generic Drugs in the Pipeline: 2017 Update

An awareness of recent drug approvals, which offer cost-effective treatment options, can help pharmacists facilitate care and improve overall outcomes.
June 16, 2017

Appropriate Use and Safety Concerns of Proton Pump Inhibitors

Although these agents are effective acid suppressants, the use of PPIs is frequently debated based on reports of new potential adverse events.
June 16, 2017

An Overview of Generic Triptans for Migraine

Triptans, as combination therapy or monotherapy, are the first-line option for the treatment of migraine in adults aged 12 years and older.
June 16, 2017

AAM Update on the Status of Generic Drugs

The name change of the Generic Pharmaceutical Association to the Association for Accessible Medicines reflects a new identity that better represents the organization’s mission of making medications more accessible to individuals who need them.
June 16, 2017

Getting a Handle on Generic-Drug Prices

Competition is the key cost driver, and the challenge is striking a balance between corporate profitability and the health needs of the public.

February 16, 2017

Biosimilars in Oncology

WEB EXCLUSIVE: With the patents set to expire for a number of monoclonal antibodies, interest related to cancer biosimilars has expanded.

December 16, 2016

Legal Aspects of Biosimilars

The recent introduction of biosimilars into the U.S. market creates the need for an understanding of FDA and state regulations.

November 17, 2016

The Impact of Generic Medications on Breast Cancer Prevention

Cost savings from generic medications have significantly increased adherence rates, and the impact of these medications on breast cancer survival rates is expected to be significant.